What We Do Platform Why NeuroSift Who We Serve Testimonials Team Contact Get Started →
FDA Breakthrough Device HIPAA Compliant
AI Digital Biomarkers · Early Detection

Catch cognitive decline years before symptoms.

AI-powered remote assessments analyze vocal micro-tremors, speech patterns, and motor skills to detect early-stage Alzheimer's and neurological decline — from any browser.

94%
Detection sensitivity
8-12yrs
Early detection window
12min
Average assessment time
Vocal AnalysisPatient #N-7821

"The rainbow arches across the sky, a bridge of colors connecting the earth to the heavens."

47 acoustic features · 12ms granularityAI Confidence 96.4%
Signal 01 — The Subtle Signals

What predicts cognitive decline, years early

Alzheimer's begins 10-20 years before symptoms. We listen for it that early.

The Challenge

Alzheimer's and other neurodegenerative diseases begin developing 10-20 years before clinical symptoms appear. Traditional cognitive tests (MMSE, MoCA) only catch disease after significant brain damage has occurred.

The NeuroSift Solution

Our AI platform analyzes micro-tremors in vocal cords, speech articulation patterns, and fine motor control during interactive browser-based exercises — detecting neurological changes with 94% sensitivity, years before physical symptoms manifest.

Remote
12-Minute Assessment
AI-Powered Analysis
🎤 Vocal Analysis
✍️ Motor Assessment
🧠 Cognitive Mapping
Signal 02 — The Neuro-AI Assessment Stack

Four AI layers, one life-changing signal

Simple browser exercises, transformed into early detection.

Vocal Biomarker Analysis

AI analyzes 47 acoustic features including micro-tremor frequency, pitch variability, and articulation speed — detecting subtle vocal changes linked to early-stage Alzheimer's.

Speech AI

Motor Skill Assessment

Interactive browser games track tapping speed, trajectory accuracy, and micro-tremors during fine motor tasks — detecting cerebellar and basal ganglia dysfunction.

Motor Analysis

Cognitive Mapping Engine

Deep learning models integrate multi-modal data to create comprehensive cognitive profiles, tracking decline patterns over time with 94% sensitivity.

Deep Learning

Longitudinal Tracking

Continuous monitoring and trend analysis detect subtle changes in cognitive function over weeks and months — enabling early intervention.

Predictive AI
Signal 03 — Live Assessment

Patient #N-7821, AI confidence 96.4%

Vocal Articulation Test

Read the paragraph below. Our AI analyzes micro-tremors and speech patterns.

"The rainbow arches across the sky, a bridge of colors connecting the earth to the heavens above."

AI analyzing: 47 acoustic features · 12ms granularity

🎤 Vocal ✍️ Motor 🧠 Cognitive 📝 Memory
Vocal Tremor
4.2 Hz variation
Normal
Motor Latency
0.47s response time
Borderline
Cognitive Load
87% accuracy
Stable
Longitudinal Trend
+2.3% vs baseline
Improving
18%
Overall Risk Score — Low risk, no intervention needed
Signal 04 — The Clinical Impact

Real outcomes from leading neurology centers

8-12yrs

Earlier detection vs. traditional cognitive assessments

94%

Detection sensitivity in clinical validation studies

12min

Complete assessment time — patient-friendly

98.2%

Patient satisfaction rate with remote assessments

"Early detection is the single most powerful tool in the fight against Alzheimer's."

Signal 05 — Who We Serve

Built for neurological care

NeuroSift empowers every stakeholder in cognitive healthcare.

Neurologists

Get objective, quantitative data on cognitive decline to support clinical decisions.

Primary Care Physicians

Screen patients remotely for early signs of cognitive impairment during routine checkups.

Memory Clinics

Monitor patients between visits with continuous, at-home cognitive assessments.

Clinical Research

Accelerate clinical trials with standardized, remote cognitive endpoint collection.

Signal 06 — What Neurologists Say

Trusted by leading neurology centers worldwide

★★★★★
"NeuroSift detected vocal micro-tremors in a patient who scored perfectly on the MMSE. 14 months later, we confirmed early-stage Alzheimer's. This technology is revolutionary."
Dr. Susan
Neurologist, Mayo Clinic
★★★★★
"We've reduced unnecessary referrals by 60%. The AI's ability to distinguish normal aging from pathological decline is truly remarkable."
Dr. Robert
Chief of Neurology, Kaiser Permanente
★★★★★
"Our patients love the 12-minute, at-home assessments. We're now catching cognitive decline 5-7 years earlier than we ever could before."
Dr. Maria
Director, UCSF Memory and Aging Center
Signal 07 — The Neuroscience Team

Neurologists, AI researchers and data scientists

Dr. ABDULRAZAQ UMAR

Dr. Abdulrazaq Umar

CEO & Co-Founder

Neurologist specializing in neurodegenerative diseases. Former faculty at Harvard Medical.

Dr. Emily Zhang

Dr. Eche Wilson

CTO & Co-Founder

AI/ML expert with specialization in speech processing and digital biomarkers.

Dr. Lisa Martinez

Dr. Linda James

Head of Clinical Research

Clinical psychologist with 20+ years in cognitive assessment validation.

Dr. Alan Kim

Dr. Ann Joseph

VP of Product

Cognitive science PhD. Former product lead at a top digital therapeutics company.

Signal 08 — Get In Touch

Ready to sift for early detection?

Tell us about your practice or research, and we'll show you how NeuroSift can help.

Email
info@neurosift.com
24/7 Support
+2348066232342
Address
Apartment 1 white house beside Methodist Church Ankpa Quarters Road, Makurdi
Urgent Cognitive ConsultFor rapid cognitive assessment needs, our team of neurologists is available for urgent consults. We prioritize early detection.+2348066232342
Signal 09 — Onboarding Sequence

Start detecting cognitive decline today

Deploy NeuroSift in your practice in days. Start catching Alzheimer's years before symptoms appear.

1

Set Up

Get your practice set up with our HIPAA-compliant assessment platform in under 2 hours.

2

Assess

Patients complete the 12-minute assessment from any browser, anywhere.

3

Intervene

Receive AI-powered reports with early detection insights and intervention recommendations.

Start Your Free Trial